和黄医药(00013.HK) 表示,国家药监局药品审评中心将沃瑞沙和泰瑞沙纳入突破性治疗药物品种,用于治疗伴有MET扩增的接受表皮生长因子受体抑制剂治疗后疾病进展的EGFR突变阳性局部晚期或转移性非小细胞肺癌患者。
沃瑞沙是一种强效、高选择性的口服MET酪氨酸激酶抑制剂。泰瑞沙是一种不可逆的第三代EGFR TKI。该联合疗法目前正在一项进行中的多中心、开放标签、随机对照的SACHI中国III期研究中进行评估。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-11 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.